The adipokine profile of metabolically benign obese and at-risk normal weight postmenopausal women: The Women's Health Initiative Observational Study

Obesity

Volumn 22, Issue 3, 2014, Pages 786-794

  Khan, Unab I ^a   Ogorodnikova, Alexandra D ^a   Xu, Linzhi ^a   Wang, Dan ^a   Wassertheil Smoller, Sylvia ^a   Ho, Gloria Y F ^a   Sowers, Mary Fran R ^b   Rajpathak, Swapnil N ^a   Allison, Matthew A ^c   Mackey, Rachel H ^d   Vitolins, Mara Z ^e   Manson, Joann E ^f   Wildman, Rachel P ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; RESISTIN;

ADULT; AGED; ARTICLE; BODY SIZE; CARDIOMETABOLIC RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; OBSERVATIONAL STUDY; PHENOTYPE; POSTMENOPAUSE; PROTEIN ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SELF REPORT; WOMEN'S HEALTH;

ADIPONECTIN; AGED; CASE-CONTROL STUDIES; FEMALE; HEALTH BEHAVIOR; HUMANS; LEPTIN; LOGISTIC MODELS; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; OVERWEIGHT; POSTMENOPAUSE; RESISTIN; RISK FACTORS;

EID: 84895817262     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20139     Document Type: Article

References (40)

1. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F,. Prevalence of uncomplicated obesity in an italian obese population. Obes Res 2005; 13: 1116-1122.
2. Karelis AD, Brochu M, Rabasa-Lhoret R,. Can we identify metabolically healthy but obese individuals (mho)?. Diabetes Metab 2004; 30: 569-572.
3. Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the us population (nhanes 1999-2004). Arch Intern Med 2008; 168: 1617-1624.
4. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET,. Metabolic and body composition factors in subgroups of obesity: What do we know?. J Clin Endocrinol Metab 2004; 89: 2569-2575.
5. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S,. The metabolically obese, normal-weight individual revisited. Diabetes 1998; 47: 699-713.
6. Sims EA,. Are there persons who are obese, but metabolically healthy?. Metabolism 2001; 50: 1499-1504.
7. Ahima RS, Flier JS,. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 327-332.
8. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW,. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
9. Maury E, Brichard SM,. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010; 314: 1-16.
10. Wildman RP, Kaplan R, Manson JE, et al. Body size phenotypes and inflammation in the women's health initiative observational study. Obesity (Silver Spring) 2011; 19: 1482-1491.
11. Koster A, Stenholm S, Alley DE, et al. Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity (Silver Spring) 2010; 18: 2354-2361.
12. Labruna G, Pasanisi F, Nardelli C, et al. High leptin/adiponectin ratio and serum triglycerides are associated with an "at-risk" phenotype in young severely obese patients. Obesity (Silver Spring) 2011; 19: 1492-1496.
13. Iacobellis G, Pistilli D, Gucciardo M, et al. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine 2005; 29: 251-255.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
15. Friedewald WT, Levy RI, Fredrickson DS,. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
16. Kaplan RC, McGinn AP, Baird AE, et al. Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the women's health initiative observational study. J Stroke Cerebrovasc Dis 2008; 17: 344-355.
17. Wassertheil-Smoller S, Kooperberg C, McGinn AP, et al. Lipoprotein-associated phospholipase a2, hormone use, and the risk of ischemic stroke in postmenopausal women. Hypertension 2008; 51: 1115-1122.
18. Third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. Circulation 2002; 106: 3143-3421.
19. Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91: 2906-2912.
20. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008; 168: 1609-1616.
21. Aguilar-Salinas CA, Garcia EG, Robles L, et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 2008; 93: 4075-4079.
22. Bluher M,. The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr Opin Lipidol 2010; 21: 38-43.
23. Karelis AD, Faraj M, Bastard JP, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 2005; 90: 4145-4150.
24. Koster A, Stenholm S, Alley DE, et al. Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity (Silver Spring) 2010; 217: 2354-2361.
25. You T, Ryan AS, Nicklas BJ,. The metabolic syndrome in obese postmenopausal women: relationship to body composition, visceral fat, and inflammation. J Clin Endocrinol Metab 2004; 89: 5517-5522.
26. Labruna G, Pasanisi F, Nardelli C, et al. High leptin/adiponectin ratio and serum triglycerides are associated with an "at-risk" phenotype in young severely obese patients. Obesity (Silver Spring) 2011; 19: 1492-1496.
27. Gomez-Ambrosi J, Fruhbeck G,. Evidence for the involvement of resistin in inflammation and cardiovascular disease. Curr Diabetes Rev 2005; 1: 227-234.
28. Vidal-Puig A, O'Rahilly S,. Resistin: a new link between obesity and insulin resistance?. Clin Endocrinol (Oxf) 2001; 55: 437-438.
29. Khan UI, Wang D, Thurston RC, et al. Burden of subclinical cardiovascular disease in "metabolically benign" and "at-risk" overweight and obese women: the study of women's health across the nation (swan). Atherosclerosis 2011; 217: 179-186.
30. Marini MA, Succurro E, Frontoni S, et al. Metabolically healthy but obese women have an intermediate cardiovascular risk profile between healthy nonobese women and obese insulin-resistant women. Diabetes Care 2007; 30: 2145-2147.
31. Ogorodnikova AD, Kim M, McGinn AP, Muntner P, Khan U, Wildman RP,. Incident cardiovascular disease events in metabolically benign obese individuals. Obesity (Silver Spring) 2012; 20: 651-659.
32. Dvorak RV, DeNino WF, Ades PA, Poehlman ET,. Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes 1999; 48: 2210-2214.
33. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB,. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third national health and nutrition examination survey, 1988-1994. Arch Intern Med 2003; 163: 427-436.
34. Ogorodnikova AD, Kim M, McGinn A, Muntner P, Khan U, Wildman PR,. Incident cardiovascular disease events in metabolically benign obese individuals. Obesity (Silver Spring) 2011; (in press)
35. Ceddia RB, William WN, Jr., Curi R,. Comparing effects of leptin and insulin on glucose metabolism in skeletal muscle: Evidence for an effect of leptin on glucose uptake and decarboxylation. Int J Obes Relat Metab Disord 1999; 23: 75-82.
36. Aleffi S, Petrai I, Bertolani C, et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005; 42: 1339-1348.
37. Ouchi N, Walsh K,. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 24-30.
38. Skurk T, Alberti-Huber C, Herder C, Hauner H,. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007; 92: 1023-1033.
39. Motoshima H, Wu X, Sinha MK, et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 2002; 87: 5662-5667.
40. Veilleux A, Caron-Jobin M, Noel S, Laberge PY, Tchernof A,. Visceral adipocyte hypertrophy is associated with dyslipidemia independent of body composition and fat distribution in women. Diabetes 2011; 60: 1504-1511.